

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SUN PHARMACEUTICAL INDUSTRIES LTD.,
Petitioner,

v.

MERCK SHARP & DOHME CORP.,
Patent Owner.

IPR2020-01072
Patent 7,326,708 B2

Before SHERIDAN K. SNEDDEN, ROBERT A. POLLOCK, and
TIMOTHY G. MAJORS, *Administrative Patent Judges*.

MAJORS, *Administrative Patent Judge*.

DECISION
Granting Institution of *Inter Partes* Review
35 U.S.C. § 314
Granting Motion for Joinder
35 U.S.C. § 315(c); 37 C.F.R. § 42.122

I. INTRODUCTION

Sun Pharmaceutical Industries Ltd. (“Petitioner”),¹ on June 12, 2020, filed a Petition for *inter partes* review of claims 1–4, 17, 19, and 21–23 of U.S. Patent No. 7,326,708 B2 (Ex. 1001, “the ’708 patent”). Paper 3 (“Pet.” or “Petition”). Petitioner also filed a Motion for Joinder (Paper 2, “Mot.” or “Motion”) with *Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-00040, in which Mylan is challenging the patentability of those same claims of the ’708 patent (“Mylan IPR”). We instituted *inter partes* review of the Mylan IPR on May 12, 2020. Mylan IPR, Paper 21.

On July 10, 2020, Merck Sharp & Dohme Corp. (“Patent Owner” or “Merck”) filed an Opposition (“Opp.” or “Opposition”) to Petitioner’s Motion for Joinder. Paper 7. Petitioner filed a Reply in support of the Motion. Paper 9 (“Mot. Reply”). And, on August 14, 2020, Patent Owner filed a Preliminary Response to the Petition. Paper 11 (“Prelim. Resp.”).

A. Related Proceedings

The parties identify several proceedings where the ’708 patent is being asserted, including: *Merck Sharp & Dohme Corp. v. Mylan Pharm. Inc. et al.*, 1:19-cv-00101 (N.D. W. Va); *Merck Sharp & Dohme Corp. v. Mylan Pharm. Inc. et al.*, 1:19-cv-01489 (D. Del.); *Merck Sharp & Dohme Corp. v. Sun Pharmaceutical Industries Ltd.*, 1:19-cv-00319 (D. Del); *Merck Sharp & Dohme Corp. v. Watson Pharmaceuticals, Inc.*, 1:19-cv-00317 (D. Del.), *Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA, Inc.*,

¹ Petitioner identifies Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. as the real parties-in-interest. Pet. 6.

IPR2020-01072
Patent 7,326,708 B2

1:19-cv-00318 (D. Del.); and *Merck Sharp & Dohme Corp. v. Dr. Reddy's Laboratories Ltd.*, 1:20-cv-00847 (D. Del.). Pet. 6–7 (listing cases); Paper 5, 2–3 (Patent Owner's Mandatory Notices). As Merck has explained, its lawsuits against several generic drug companies related to the '708 patent, including suits identified above, have been consolidated for pretrial purposes in a multidistrict litigation. See Mylan IPR, Paper 10, 10 (identifying *In re Sitagliptin Phosphate ('708 & '921) Patent Litig.* C.A. No. 19-md-2902-RGA (D. Del.)).

In addition to the Mylan IPR, Patent Owner identifies the following related administrative matters pending before the Patent Office: *Teva Pharmaceuticals USA, Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-01045; and *Dr. Reddy's Laboratories, Inc. v. Merck Sharp & Dohme Corp.*, IPR2020-01060. Paper 5, 3.²

² Petitioners in these related matters filed their petitions at or about the same time as the present Petition. Those other petitioners similarly move for joinder with the Mylan IPR. See, e.g., IPR2020-1060, Paper 3.

B. Asserted Grounds of Unpatentability

Petitioner asserts six grounds of unpatentability (Pet. 12–13) as set forth in the table below:

Claim(s) Challenged	35 U.S.C. §	Reference(s)/Basis
1–3, 17, 19, 21–23	102 ³	WO '498 ⁴
1–3, 17, 19, 21–23	102	the '871 patent ⁵
3, 17, 19, 21–23	103	WO '498
1–3, 17, 19, 21–23	103	WO '498, Bastin ⁶
4	103	WO '498, Bastin, Brittain ⁷
4	103	WO '498, Brittain

³ The Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) (“AIA”), amended 35 U.S.C. §§ 102 and 103. Because the challenged claims of the '708 patent have an effective filing date before the effective date of the applicable AIA amendments, we refer to the pre-AIA versions of 35 U.S.C. §§ 102 and 103 in this Decision.

⁴ Edmondson et al., WO 03/004498 A1, published Jan. 16, 2003 (Ex. 1004, “WO '498”). WO '498 published from Application No. PCT/US02/21349, filed July 5, 2002, which claims priority to US Provisional Application No. 60/303,474, filed July 6, 2001 (Ex. 1012).

⁵ Edmondson et al., US 6,699,871 B2, issued Mar. 2, 2004 (Ex. 1007, “the '871 patent”). The '871 patent issued from an application filed July 5, 2002, and claims priority to US Provisional Application No. 60/303,474, filed July 6, 2001 (Ex. 1012).

⁶ Richard J. Bastin et al., *Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities*, 4 ORGANIC PROCESS RESEARCH & DEVELOPMENT 427–435, 2000 (Ex. 1006, “Bastin”).

⁷ Polymorphism in Pharmaceutical Solids, Harry G. Brittain ed., 1999 (Ex. 1005, “Brittain”).

Petitioner also cites the declaration of Dr. Steven Baldwin (Ex. 1002), but has indicated that it will withdraw Dr. Baldwin's declaration, and will rely instead on the testimony of Mylan's declarant, Dr. Mukund Chorghade, in the Mylan IPR if permitted. Mot. 4.

II. INSTITUTION OF INTERPARTES REVIEW

The Petition advances the same grounds of unpatentability that are included in the instituted Mylan IPR. *Compare* Pet. 13–71, *with* Mylan IPR, Paper 1, 12–69; *see also* Mylan IPR, Paper 21, 4–5, 64 (Institution Decision). Indeed, Petitioner “asserts that the same claims are invalid based on substantially the same arguments presented in the Mylan IPR,” and that “Petitioner’s declaration is substantively identical to the declaration in the Mylan IPR.” Mot. 1; *see also id.* at 4 (“Along with its Motion for Joinder, Petitioner here has simultaneously filed a ‘me too’ Petition” for IPR based on the “same reasons set forth in the Mylan IPR.”). We conclude the Petition is properly characterized as a “me-too” challenge relative to the petition in the Mylan IPR.

Merck filed a Preliminary Response, agreeing that “[t]he Petition at issue is a ‘Me-Too’ petition,” that was filed with a timely motion for joinder. Prelim. Resp. 1.⁸ Merck notes the preliminary arguments it raised in response to the petition in the Mylan IPR. *Id.* But, recognizing that the Board granted institution in the Mylan IPR notwithstanding those

⁸ Patent Owner’s Preliminary Response does not include page numbers, but we treat as though it includes pages 1–4, with page 1 beginning after the caption page.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.